Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second, Phase III Clinical Trial to Evaluate Proxalutamide and Abiraterone as the First-line Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Next Previous
Trial Profile

Second, Phase III Clinical Trial to Evaluate Proxalutamide and Abiraterone as the First-line Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Pruxelutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Suzhou Kintor Pharmaceuticals

Most Recent Events

  • 25 Mar 2022 According to a Kintor Pharmaceuticals media release, the company finished enrollment of 718 patients in the study on 24 February 2022.
  • 25 Mar 2022 Status changed from recruiting to active, no longer recruiting, according to a Kintor Pharmaceuticals media release.
  • 31 Jan 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top